세계의 방사면역측정법 시장 : 시장 규모, 점유율, 동향 분석(제품별, 용도별, 최종 용도별, 지역별), 부문별 예측(2025-2030년)

Radioimmunoassay Market Size, Share & Trends Analysis Report By Product (Analyzers, Reagents & Kits), By Application (Research, Clinical Diagnostics), By End Use (Hospitals, Laboratory), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 방사면역측정법 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 방사면역측정법 시장 규모는 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 2.93%를 기록해, 2030년에는 17억 9,000만 달러에 이를 전망입니다.

시장 성장의 원동력은 민감하고 특이적인 진단 응용 분야에서 RIA의 중요한 역할입니다. UNAIDS에 의하면, 2023년에는 세계에서 3,990만명 가까이 HIV에 감염되어, 130만명이 새롭게 감염하고 있어 RIA와 같은 정확하고 신뢰성이 높은 검사 수법에 대한 지속적인 요구가 반영되고 있습니다. 또한, 갑상선 질환이나 특정의 암의 이환율 증가에 의해 정밀한 내분비 및 종양 진단 수요가 증가하고 있습니다.

RIA 기술과 시약의 최근 진보도 시장 성장에 기여하고 있습니다. Medipan GmbH와 같은 기업은 TSH, Tg, 칼시토닌용 RIA 키트의 보존 가능기간을 연장해, 검사실 효율을 향상시키고 있습니다. 또한 2022년에 발매된 동사의 합리화된 SELco Trab 1-step 분석은 갑상선 항체의 검출에 필요한 시간과 워크플로우의 간편성을 개선했습니다.

방사면역측정법 시장은 임상진단과 연구 모두 관련성에 의해 형성되고 있습니다. LabLogic Systems와 같은 고급 분석기와 자동 감마 카운터의 도입은 RIA 워크플로의 현대화를 지원하고 높은 처리량 용도에 대한 액세스를 확장합니다.

실험실 칩(LOC) 기술의 발전은 기존의 방사면역측정법(RIA)에 혁명을 일으켰습니다. 마이크로유체 RIA 플랫폼(μ-RIA)의 개발로 분석 시간이 약 5분으로 크게 단축되었고 시약 소비도 최소화되었습니다. 이러한 개선은 장기간의 인큐베이션과 방사성 폐기물의 발생과 같은 기존의 RIA의 한계를 다루며 임상 진단에서 이 기술의 적용성을 높이는 것입니다. 이러한 개발은 방사성 표지 및 방사면역측정법 기법을 개선하고 영상 진단 및 표적 진단에서 보다 높은 정확도, 효율성 및 안전성을 목표로 하는 협력적인 노력을 강조합니다. 최근 2025년 3월 앨버타 대학의 연구자들은 단일클론항체 파니투무맙과 방사성 동위원소 구리-64를 결합한 새로운 분자 이미징 검사를 발표했습니다. 파니투무맙은 비소세포 폐암세포에서 일반적으로 과발현되는 상피성장인자 수용체(EGFR)를 표적으로 합니다. 구리-64로 표지되면, 이 접합체는 정밀한 PET 이미징을 가능하게 하고, 폐암의 조기 발견 및 모니터링을 용이하게 합니다. 이 하이브리드 접근법은 전통적인 생검을 대체하는 비침습적인 옵션을 제공하며 적시에 개입하여 환자 결과를 향상시킬 수 있습니다.

방사면역측정법 시장 : 분석 개요

• 제품별로는 2024년에 시약 및 키트가 73.23%의 수익 점유율로 시장을 선도했습니다. 이러한 키트는 일반적으로 방사선 표식 항원 또는 항체(일반적으로 요오드 125를 사용), 완충액, 표준품, 분리 시약이 포함되어 있습니다. PerkinElmer나 DIAsource ImmunoAssays는 갑상선 기능 검사(TSH나 칼시토닌 등), 불임 호르몬, 종양 마커용의 폭넓은 RIA 키트를 제공하고 있어 일상적인 스크리닝이나 특수한 진단을 서포트하고 있습니다. 한편, 분석 장치는 예측 기간 중에 가장 급성장하는 부문이 될 전망입니다.
• 2024년의 방사면역측정법 산업을 용도별로 살펴보면 루틴검사나 전문적인 의료검사에 RIA기술이 널리 사용되고 있기 때문에 임상진단이 수익 기준으로 76.33%의 점유율을 차지해 업계를 선도했습니다. 이 우위성은 주로 미량 농도의 생물학적 마커를 검출할 때의 이 수법의 탁월한 감도와 특이성에 기인하고 있어 정확한 진단, 질환 모니터링, 치료 방침의 결정에 매우 귀중한 것이 되고 있습니다.
• 병원은 2024년 32.54%의 판매 점유율로 시장의 최종 용도 부문을 선도했는데, 이는 병원의 종합적인 진단 능력과 정확한 바이오마커 검출이 필요한 질병의 유병률 증가로 인한 것입니다. 저농도의 호르몬, 약제, 기타 물질을 정확하게 측정하기 위해, 병원 환경에 있어서 불가결한 것이 되고 있습니다. 또한, 병원에서의 자동화된 고도의 RIA 시스템의 채용에 의해 워크 플로우가 합리화되어, 납기가 단축되어, 결과의 정확성이 향상하고 있습니다.
• 세계의 방사면역측정법 시장은 2024년에는 북미가 47.43%의 매출 점유율로 지배적이었습니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 방사면역측정법 시장 : 변동 요인, 경향, 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회 분석
  • 공급망 분석
  • 유통 채널
• 방사면역측정법 시장 : 분석 도구
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석
• 의료비 상환의 개요
• 가격 분석

제4장 방사면역측정법 시장 : 제품별 추정 및 동향 분석

• 부문 대시보드
• 방사면역측정법 시장 : 변동 분석, 제품별(2024년 및 2030년)
• 분석장치
• 시약 및 키트

제5장 방사면역측정법 시장 : 용도별 추정 및 동향 분석

• 부문 대시보드
• 방사면역측정법 시장 : 변동 분석, 용도별(2024년 및 2030년)
• 연구
• 임상 진단

제6장 방사면역측정법 시장 : 최종 용도별 추정 및 동향 분석

• 부문 대시보드
• 방사면역측정법 시장 : 변동 분석, 최종 용도별(2024년 및 2030년)
• 병원
• 임상 진단실험실
• 제약업계
• 기타

제7장 방사면역측정법 시장 : 지역별 추정 및 동향 분석

• 방사면역측정법 시장 점유율 : 지역별(2024년 및 2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 덴마크
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 남아프리카
  • 쿠웨이트

제8장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출기업별
• 기업 분류
• 세계 기업의 시장 점유율 분석(2024년)
• 기업 히트맵 분석
• 전략 매핑
  • 확대
  • 기업 인수합병(M&A)
  • 파트너십 및 협업
  • 신제품 발매
  • 연구개발
• 기업 프로파일
  • DIAsource
  • Tecan Trading AG
  • PerkinElmer
  • DRG International Inc.
  • Oxford BioSystems
  • DiaSorin SpA
  • Eurodiagnostico, SL
  • MP Biomedicals
  • Merck KGaA

JHS

영문 목차

영문목차

Radioimmunoassay Market Growth & Trends:

The global radioimmunoassay market size is expected to reach USD 1.79 billion by 2030, registering a CAGR of 2.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by its critical role in highly sensitive and specific diagnostic applications. RIA remains a major solution for the detection of minute concentrations of hormones, drugs, tumor markers, and infectious agents despite the rise of newer immunoassay techniques. A key market driver is the rising prevalence of chronic and infectious diseases worldwide. According to UNAIDS, nearly 39.9 million people globally were living with HIV in 2023, with 1.3 million new infections, reflecting the ongoing need for accurate and reliable testing methodologies such as RIA. In addition, the increasing incidence of thyroid disorders and certain cancers has amplified the demand for precise endocrine and oncology diagnostics.

Recent advancements in RIA technologies and reagents have also contributed to market growth. Companies such as Medipan GmbH have enhanced the shelf life of RIA kits for TSH, Tg, and Calcitonin, improving laboratory efficiency. Additionally, their streamlined SELco TRAb 1-step assay, launched in 2022, has improved turnaround time and workflow simplicity in detecting thyroid antibodies. Strategic collaborations and acquisitions further highlight market consolidation and innovation. For instance, DiaSorin's acquisition of Luminex Corporation has expanded its multiplex testing capabilities, reinforcing its position in specialty diagnostics, including RIA. Moreover, DIAsource's milestone agreement with Svar Life Science (formerly Euro Diagnostica) supports the development of advanced immunoassay solutions, further boosting RIA technology dissemination.

The radioimmunoassay market is also shaped by its relevance in both clinical diagnostics and research. Clinical settings, especially hospitals and diagnostic laboratories, account for a substantial market share due to the routine use of RIA in hormonal assays and allergy testing. Meanwhile, research laboratories drive the fastest growth, utilizing RIA's high specificity for biomedical studies. The introduction of advanced analyzers and automated gamma counters, like those from LabLogic Systems, supports the modernization of RIA workflows and widens access to high-throughput applications.

Advancements in lab-on-a-chip (LOC) technology have revolutionized traditional radioimmunoassay (RIA). The development of microfluidic RIA platforms, or μ-RIA, has significantly reduced analysis times to approximately five minutes and minimized reagent consumption. These improvements address previous limitations of RIA, such as lengthy incubation periods and radioactive waste production, thereby enhancing the technique's applicability in clinical diagnostics. These developments underscore a concerted effort to refine radioactive labeling and radioimmunoassay methodologies, aiming for greater precision, efficiency, and safety in diagnostic imaging and targeted. Recently, in March 2025, researchers from the University of Alberta introduced a novel molecular imaging test that combines the monoclonal antibody panitumumab with the radioisotope copper-64. Panitumumab targets the epidermal growth factor receptor (EGFR), commonly overexpressed in non-small-cell lung cancer cells. When labeled with copper-64, this conjugate enables precise PET imaging, facilitating early detection and monitoring of lung cancer. This hybrid approach offers a non-invasive alternative to traditional biopsies, potentially improving patient outcomes through timely intervention.

Radioimmunoassay Market Report Highlights:

• The reagent and kits led the product segment in 2024 with a 73.23% revenue share. The increasing demand for reliable diagnostic tools in endocrine, oncology, infectious disease, and autoimmune disorder testing has significantly boosted the consumption of RIA reagents and kits across laboratories and hospitals. These kits typically include radioactively labeled antigens or antibodies (commonly using Iodine-125), buffers, standards, and separation reagents. The high sensitivity and specificity of these kits make them indispensable in clinical laboratories for detecting hormones such as TSH, insulin, cortisol, testosterone, and estradiol. For example, PerkinElmer and DIAsource ImmunoAssays offer a wide range of RIA kits for thyroid function testing (like TSH and Calcitonin), fertility hormones, and tumor markers, supporting routine screening and specialized diagnostics. Whereas analyzers is expected to be the fastest-growing segment during the forecast period.
• The clinical diagnostics led the application segment in the radioimmunoassay industry in 2024 with a 76.33% share in terms of revenue, owing to the widespread use of RIA techniques for routine and specialized medical testing. This dominance is primarily attributed to the method's exceptional sensitivity and specificity in detecting minute concentrations of biological markers, making it invaluable for accurate diagnosis, disease monitoring, and therapeutic decision-making. Whereas research is expected to be the fastest-growing segment during the forecast period.
• The hospital led the end use segment in the market in 2024 with a 32.54% revenue share, driven by the hospitals' comprehensive diagnostic capabilities and the increasing prevalence of diseases requiring precise biomarker detection. RIA's exceptional sensitivity and specificity make it indispensable in hospital settings for accurately measuring low concentrations of hormones, drugs, and other substances in patient samples. In addition, the adoption of automated and advanced RIA systems in hospitals has streamlined workflows, reduced turnaround times, and improved result accuracy.
• North America dominated the global market for radioimmunoassay with a revenue share of 47.43% in 2024. The growth is driven by the presence of advanced healthcare infrastructure, robust research and development (R&D) activities, and a high prevalence of chronic diseases necessitating precise diagnostic tools. Further, supportive policies and reimbursement frameworks enhance the adoption and integration of RIA in clinical diagnostics.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Regional Scope
• 1.4. Estimates and Forecast Timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
• 1.7. Details of primary research
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.1.1. Approach 1: Commodity flow approach
  • 1.9.2. Volume price analysis (Model 2)
    • 1.9.2.1. Approach 2: Volume price analysis
• 1.10. Research Scope and Assumptions
  • 1.10.1. List of Secondary Sources
  • 1.10.2. List of Primary Sources
  • 1.10.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Radioimmunoassay Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising Prevalence 0f Chronic and Infectious Diseases
    • 3.2.1.2. High Sensitivity and Specificity of RIA Techniques
    • 3.2.1.3. Advancements in Radiolabeled Reagents and Assay Technologies
    • 3.2.1.4. The Rising Amount of Blood Donations in Blood Banks
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Presence of Ambiguous Regulatory Framework
    • 3.2.2.2. High Cost of RIA Equipment
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Supply Chain Analysis
  • 3.2.5. Distribution Channel
    • 3.2.5.1. Direct Sales
    • 3.2.5.2. Distributors Network
    • 3.2.5.3. E-commerce and Online Platforms
    • 3.2.5.4. Major Distributors
• 3.3. Radioimmunoassay Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Legal landscape
• 3.4. Reimbursement Overview
• 3.5. Pricing Analysis

Chapter 4. Radioimmunoassay Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Radioimmunoassay Market: Product Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Analyzers
  • 4.3.1. Analyzers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Reagents and Kits
  • 4.4.1. Reagents and Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Radioimmunoassay Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Radioimmunoassay Market: Application Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Research
  • 5.3.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Clinical Diagnostics
  • 5.4.1. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Radioimmunoassay Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Radioimmunoassay Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Hospitals
  • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Clinical Diagnostics Laboratories
  • 6.4.1. Clinical Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Pharmaceutical Industries
  • 6.5.1. Pharmaceutical Industries Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Radioimmunoassay Market: Regional Estimates & Trend Analysis

• 7.1. Radioimmunoassay Market Share, By Region, 2024 & 2030 (USD Million)
• 7.2. North America
  • 7.2.1. North America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.2.2.3. Competitive Insights
    • 7.2.2.4. U.S. Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.2.3.3. Competitive Insights
    • 7.2.3.4. Canada Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.2.4.3. Competitive Insights
    • 7.2.4.4. Mexico Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.2.3. Competitive Insights
    • 7.3.2.4. UK Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.3.3. Competitive Insights
    • 7.3.3.4. Germany Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.4.3. Competitive Insights
    • 7.3.4.4. France Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.5.3. Competitive Insights
    • 7.3.5.4. Italy Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.6.3. Competitive Insights
    • 7.3.6.4. Spain Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7. Sweden
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.7.3. Competitive Insights
    • 7.3.7.4. Sweden Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8. Denmark
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.8.3. Competitive Insights
    • 7.3.8.4. Denmark Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Regulatory Landscape/Reimbursement Scenario
    • 7.3.9.3. Competitive Insights
    • 7.3.9.4. Norway Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. China Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Japan Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. India Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.5.3. Competitive Insights
    • 7.4.5.4. South Korea Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.6.3. Competitive Insights
    • 7.4.6.4. Australia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Regulatory Landscape/Reimbursement Scenario
    • 7.4.7.3. Competitive Insights
    • 7.4.7.4. Thailand Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. Brazil Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Argentina Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Saudi Arabia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. UAE
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. UAE Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. South Africa
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. South Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Landscape/Reimbursement Scenario
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. Kuwait Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Global Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
• 8.6. Company Profiles
  • 8.6.1. DIAsource
    • 8.6.1.1. Participant's Overview
    • 8.6.1.2. Financial Performance
    • 8.6.1.3. Product Benchmarking
    • 8.6.1.4. Recent Developments
  • 8.6.2. Tecan Trading AG
    • 8.6.2.1. Participant's Overview
    • 8.6.2.2. Financial Performance
    • 8.6.2.3. Product Benchmarking
    • 8.6.2.4. Recent Developments
  • 8.6.3. PerkinElmer
    • 8.6.3.1. Participant's Overview
    • 8.6.3.2. Financial Performance
    • 8.6.3.3. Product Benchmarking
    • 8.6.3.4. Recent Developments
  • 8.6.4. DRG International Inc.
    • 8.6.4.1. Participant's Overview
    • 8.6.4.2. Financial Performance
    • 8.6.4.3. Product Benchmarking
    • 8.6.4.4. Recent Developments
  • 8.6.5. Oxford BioSystems
    • 8.6.5.1. Participant's Overview
    • 8.6.5.2. Financial Performance
    • 8.6.5.3. Product Benchmarking
    • 8.6.5.4. Recent Developments
  • 8.6.6. DiaSorin S.p.A.
    • 8.6.6.1. Participant's Overview
    • 8.6.6.2. Financial Performance
    • 8.6.6.3. Product Benchmarking
    • 8.6.6.4. Recent Developments
  • 8.6.7. Eurodiagnostico, S.L.
    • 8.6.7.1. Participant's Overview
    • 8.6.7.2. Financial Performance
    • 8.6.7.3. Product Benchmarking
    • 8.6.7.4. Recent Developments
  • 8.6.8. MP Biomedicals
    • 8.6.8.1. Participant's Overview
    • 8.6.8.2. Financial Performance
    • 8.6.8.3. Product Benchmarking
    • 8.6.8.4. Recent Developments
  • 8.6.9. Merck KGaA
    • 8.6.9.1. Participant's Overview
    • 8.6.9.2. Financial Performance
    • 8.6.9.3. Product Benchmarking
    • 8.6.9.4. Recent Developments

관련자료